Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015

JAMA Oncol. 2015 May;1(2):143-4. doi: 10.1001/jamaoncol.2015.50.

Authors

Carlo Gambacorti-Passerini¹, Rocco Piazza²

Affiliations

¹ Department of Health Sciences, University of Milano-Bicocca, Monza, Italy2Section of Hematology, San Gerardo Hospital, Monza, Italy.
² Department of Health Sciences, University of Milano-Bicocca, Monza, Italy.

PMID: 26181011
DOI: 10.1001/jamaoncol.2015.50

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Agents / adverse effects
Antineoplastic Agents / economics
Antineoplastic Agents / therapeutic use*
Cost-Benefit Analysis
Drug Costs
Humans
Imatinib Mesylate / adverse effects
Imatinib Mesylate / economics
Imatinib Mesylate / therapeutic use*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / economics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / enzymology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / mortality
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
Molecular Targeted Therapy
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / economics
Protein Kinase Inhibitors / therapeutic use*
Treatment Outcome

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Imatinib Mesylate